• Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The medication was granted an emergency...
    19 KB (1,642 words) - 04:38, 24 July 2024
  • Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together via intravenous infusion as...
    16 KB (1,301 words) - 07:13, 18 July 2024
  • antibody treatment against COVID-19, with a Phase 1 trial of LY-CoV555 (Bamlanivimab), in collaboration with Eli Lilly and Company. The drug was granted an...
    10 KB (844 words) - 18:25, 8 August 2024
  • Thumbnail for Eli Lilly and Company
    antibody, bamlanivimab (LYCoV555), found that bamlanivimab was not effective in treating people hospitalized with COVID-19, but data showed bamlanivimab might...
    162 KB (14,943 words) - 18:44, 2 November 2024
  • Thumbnail for COVID-19
    investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID‑19. Bamlanivimab is authorised for people with positive...
    288 KB (33,185 words) - 17:48, 2 November 2024
  • Thumbnail for Monoclonal antibody
    important monoclonal antibodies. In 2020, the monoclonal antibody therapies bamlanivimab/etesevimab and casirivimab/imdevimab were given emergency use authorizations...
    48 KB (4,964 words) - 04:26, 20 October 2024
  • Thumbnail for COVID-19 drug development
    between the serum and placebo groups. Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together...
    90 KB (13,195 words) - 04:28, 26 July 2024
  • (revoked, although its license for established indications remains), and bamlanivimab – all in response to the COVID-19 pandemic. On April 16, 2021, the FDA...
    12 KB (1,380 words) - 17:54, 24 February 2024
  • 2021 there were Emergency Use Authorizations for baricitinib, bamlanivimab, bamlanivimab/etesevimab, and casirivimab/imdevimab. As of July 2021, outpatient...
    67 KB (6,361 words) - 23:43, 27 October 2024
  • agent. In 2021, the US FDA gave emergency use authorization (EUA) to bamlanivimab/etesevimab for post-exposure prophylaxis against COVID-19. However, due...
    31 KB (3,370 words) - 15:50, 1 September 2024
  • Thumbnail for Coronavirus spike protein
    Authorization in the United States: bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab. Bamlanivimab/etesevimab was not recommended in the...
    76 KB (7,457 words) - 07:06, 3 October 2024
  • only on high-risk patients at an early stage of the illness. The drugs, Bamlanivimab and REGN-COV-2, had been used on US President Donald Trump after he caught...
    150 KB (14,797 words) - 21:25, 14 October 2024
  • Thumbnail for List of therapeutic monoclonal antibodies
    Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bamlanivimab and Etesevimab" (PDF). U.S. Food and Drug Administration (FDA). Archived...
    137 KB (4,083 words) - 21:25, 19 October 2024
  • Thumbnail for SARS-CoV-2 Delta variant
    COVID-19 may slow down virus evolution. In vitro experiments suggest that bamlanivimab may not be effective against Delta on its own. At high enough concentrations...
    130 KB (12,300 words) - 15:30, 24 October 2024
  • Thumbnail for Casirivimab/imdevimab
    revised the authorizations for two monoclonal antibody treatments – bamlanivimab/etesevimab (administered together) and casirivimab/imdevimab – to limit...
    49 KB (3,417 words) - 04:55, 2 November 2024
  • Thumbnail for ZMapp
    Human Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab§ Bamlanivimab† (+etesevimab)† Bebtelovimab§ Casirivimab† (+imdevimab) Cilgavimab† (+tixagevimab)†...
    24 KB (2,673 words) - 16:46, 2 November 2024
  • genetic disorder in which both arhinia and microphthalmia are present Bamlanivimab, an experimental antibody treatment for COVID-19 BAM, a ceramic alloy...
    5 KB (730 words) - 16:21, 6 August 2024
  • development: The FDA issues an emergency use authorization (EUA) for bamlanivimab and etesevimab. February 11 President Biden terminates the national emergency...
    270 KB (25,026 words) - 04:22, 5 November 2024
  • Trial (UK) Solidarity trial (WHO) Monoclonal antibodies Bamlanivimab/etesevimab Bamlanivimab Etesevimab Bebtelovimab Casirivimab/imdevimab Regdanvimab...
    180 KB (23,898 words) - 14:59, 19 August 2024
  • became the third U.S. city with a federally supported clinic offering bamlanivimab, a COVID-19 treatment. A European strain of COVID-19 initially made up...
    197 KB (18,737 words) - 15:58, 17 October 2024
  • Thumbnail for COVID-19 drug repurposing research
    ineffective against COVID-19. The use of the combination of etesevimab and bamlanivimab together was found ineffective against the Omicron variant. "Repurposing...
    128 KB (14,818 words) - 14:23, 18 October 2024
  • Thumbnail for Jason McLellan
    Eli Lilly and Company to develop their monoclonal antibody treatment bamlanivimab (LY-CoV555), which received emergency use authorization from the U.S...
    30 KB (2,830 words) - 18:33, 2 October 2024
  • option for benign prostatic hyperplasia (BPH). The institution introduced Bamlanivimab monoclonal antibody therapy, a highly effective antibody treatment against...
    5 KB (545 words) - 06:24, 28 October 2024
  • Sturgill Simpson Sturgill Simpson Cornsworth & Pinchley: Attorneys-At-Law. Bamlanivimab. Late Show Presents: Quarantine-While. Hugh Grant discusses The Undoing...
    81 KB (247 words) - 18:36, 26 March 2024
  • Thumbnail for John R. Mascola
    and Eli Lilly to isolate a SARS-CoV-2 monoclonal antibodies Ly-CoV555 (bamlanivimab) authorized for use in November 2020 and bebtelovimab authorized for...
    24 KB (2,300 words) - 06:58, 24 August 2024